Stock Alert: Sorrento Therapeutics Down 10%

Shares of Sorrento Therapeutics, Inc. (SRNE) are currently losing nearly 10% on Monday morning following the news that Yale's saliva-based COVID-19 test received emergency use authorization from FDA, while SRNE's saliva-based test is still in development.